Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.48 |
| ▸ | RARB | P10826 | 3/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7337576 | 0.84 | L3MBTL1 (0.75) | L3MBTL1LMNAGAAFFAR1S1PR1 | |
| SCHEMBL20426075 | 0.81 | LMNA (0.60) | L3MBTL1LMNAFFAR1S1PR1S1PR3 | |
| SCHEMBL24723561 | 0.80 | L3MBTL1 (0.82) | L3MBTL1LMNAGAAFFAR1S1PR1 | |
| SCHEMBL17320238 | 0.79 | LMNA (0.79) | L3MBTL1LMNAFFAR1S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL10807470 | 0.79 | L3MBTL1 (0.79) | L3MBTL1LMNAGAAFFAR1S1PR1 | |
| SCHEMBL6497674 | 0.79 | LMNA (0.79) | L3MBTL1LMNAFFAR1S1PR1S1PR3 | |
| SCHEMBL8378949 | 0.79 | LMNA (0.79) | L3MBTL1LMNAFFAR1S1PR1S1PR3 | |
| SCHEMBL3488457 | 0.79 | LMNA (0.79) | L3MBTL1LMNAFFAR1S1PR1S1PR3 | |
| SCHEMBL8558255 | 0.79 | LMNA (0.79) | L3MBTL1LMNAFFAR1S1PR1S1PR3 | |
| SCHEMBL2185137 | 0.79 | LMNA (0.79) | L3MBTL1LMNAFFAR1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2004510707-A | — | — | 2004-04-08 | — | — | JP | claimed |
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | GRANT ELFRIDA R (US) | 2003-12-04 | — | — | US | claimed |
| EP-1317266-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | claimed |
| WO-2002011724-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | GRANT ELFRIDA R (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1317266-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002011724-A2 | NEUROPROTECTIVE 2-PYRIDINAMINE COMPOSITIONS AND RELATED METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225085-A1 | 2-pyridinamine compositions and related methods | AIFM1, CASP5, CASP2 | L3MBTL1 2284/4885LMNA 265/4885GAA 3007/4885 |
| US-20020198219-A1 | 2-pyridinamine compositions and related methods | AIFM1, CASP5, CASP2 | L3MBTL1 2284/4885LMNA 265/4885GAA 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.